Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citigroup Inc. (C) vs Medtronic PLC (MDT) Price & Performance

Citigroup Inc.Trade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Citigroup Inc. vs Medtronic PLC — how do they compare? Citigroup Inc. trades at $135.87 (market cap $226.82B), while Medtronic PLC trades at $90.58 (market cap $114.45B). The key difference: Citigroup Inc. is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.22%). Which is the better fit depends on your goals.

CMDT
Market Cap
$226.82B$114.45B
Sector
FinancialsHealth
52-Week High
$145.67$105.35
52-Week Low
$92.59$73.75
Dividend Yield
1.98%3.22%
Enterprise Value
$133.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citigroup Inc.

Citigroup (C) trades at $134.99, up 0.86% with bullish technical momentum near key resistance at $136. The stock shows strong fundamental improvement with Q2 2026 EPS beating estimates at $3.15 versus $2.72 expected, marking the second consecutive quarterly beat. Revenue reached decade highs in Q2 2026 at $91.4B with net income margin improving to 19.52%. Recent strategic hires in investment banking and digital transformation initiatives support growth prospects.

The outlook remains positive with analyst consensus target of $154.38 offering 14% upside potential. Key risks include volatile cash flow patterns with negative operating cash flow in 2025 ($-67.6B) and elevated debt levels at $287.3B long-term debt. The stock's current P/E of 14.55 appears reasonable given improving profitability and strategic repositioning underway.

Medtronic PLC

Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.

The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citigroup Inc.

Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.

Read more on C

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT